PDF下载 ( 890 KB)
Hepatology｜Health-Related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebocontrolled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis
本文二维码
计量
- 文章访问数: 114
- HTML全文浏览量: 42
- PDF下载量: 14
- 被引次数: 0
下载:
